• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Investigating the Interaction between Excipients and Monoclonal Antibodies PGT121 and N49P9.6-FR-LS: A Comprehensive Analysis.辅料与单克隆抗体PGT121和N49P9.6-FR-LS之间的相互作用研究:全面分析
Mol Pharm. 2025 Apr 7;22(4):1831-1846. doi: 10.1021/acs.molpharmaceut.4c00973. Epub 2025 Mar 3.
2
Computational Characterization of Antibody-Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach.基于配体竞争饱和-生物大分子分析法的抗体-赋形剂相互作用的计算特征分析用于理性赋形剂选择。
Mol Pharm. 2020 Nov 2;17(11):4323-4333. doi: 10.1021/acs.molpharmaceut.0c00775. Epub 2020 Oct 6.
3
Molecular Computations of Preferential Interaction Coefficients of IgG1 Monoclonal Antibodies with Sorbitol, Sucrose, and Trehalose and the Impact of These Excipients on Aggregation and Viscosity.IgG1 单克隆抗体与山梨醇、蔗糖和海藻糖的优先相互作用系数的分子计算及其对聚集和黏度的影响。
Mol Pharm. 2019 Aug 5;16(8):3657-3664. doi: 10.1021/acs.molpharmaceut.9b00545. Epub 2019 Jul 17.
4
Machine Learning Models of Antibody-Excipient Preferential Interactions for Use in Computational Formulation Design.用于计算制剂设计的抗体-辅料优先相互作用的机器学习模型
Mol Pharm. 2020 Sep 8;17(9):3589-3599. doi: 10.1021/acs.molpharmaceut.0c00629. Epub 2020 Aug 25.
5
Residue-resolved insights into the stabilization of therapeutic proteins by excipients: A case study of two monoclonal antibodies with arginine and glutamate.解析辅料稳定治疗性蛋白的机制:精氨酸和谷氨酸两种单克隆抗体的案例研究
MAbs. 2024 Jan-Dec;16(1):2427771. doi: 10.1080/19420862.2024.2427771. Epub 2024 Nov 14.
6
Understanding the Role of Preferential Exclusion of Sugars and Polyols from Native State IgG1 Monoclonal Antibodies and its Effect on Aggregation and Reversible Self-Association.理解天然状态 IgG1 单克隆抗体中糖和多元醇的优先排除作用及其对聚集和可逆自组装的影响。
Pharm Res. 2019 May 24;36(8):109. doi: 10.1007/s11095-019-2642-3.
7
Site Identification by Ligand Competitive Saturation-Biologics Approach for Structure-Based Protein Charge Prediction.基于配体竞争饱和的生物大分子方法进行基于结构的蛋白电荷预测的位点鉴定。
Mol Pharm. 2023 May 1;20(5):2600-2611. doi: 10.1021/acs.molpharmaceut.3c00064. Epub 2023 Apr 5.
8
Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody.组氨酸和蔗糖对单克隆抗体生物物理性质的影响
Pharm Res. 2017 Mar;34(3):629-639. doi: 10.1007/s11095-016-2092-0. Epub 2016 Dec 29.
9
Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies.辅料差异影响两种 IgG1 单克隆抗体的构象稳定性和预过渡动力学。
J Pharm Sci. 2012 Sep;101(9):3062-77. doi: 10.1002/jps.23187. Epub 2012 May 11.
10
Bilateral Effects of Excipients on Protein Stability: Preferential Interaction Type of Excipient and Surface Aromatic Hydrophobicity of Protein.辅料对蛋白质稳定性的双侧效应:辅料的优先相互作用类型与蛋白质表面芳香族疏水性
Pharm Res. 2017 Jul;34(7):1378-1390. doi: 10.1007/s11095-017-2152-0. Epub 2017 Apr 11.

引用本文的文献

1
Harnessing computational technologies to facilitate antibody-drug conjugate development.利用计算技术促进抗体药物偶联物的开发。
Nat Chem Biol. 2025 Jun 27. doi: 10.1038/s41589-025-01950-z.

本文引用的文献

1
Optimizing Excipient Properties to Prevent Aggregation in Biopharmaceutical Formulations.优化赋形剂性质以防止生物制药制剂中聚集。
J Chem Inf Model. 2024 Jan 8;64(1):265-275. doi: 10.1021/acs.jcim.3c01898. Epub 2023 Dec 19.
2
A systematic review of commercial high concentration antibody drug products approved in the US: formulation composition, dosage form design and primary packaging considerations.美国批准的商业化高浓度抗体药物产品的系统评价:制剂组成、剂型设计和初级包装考虑因素。
MAbs. 2023 Jan-Dec;15(1):2205540. doi: 10.1080/19420862.2023.2205540.
3
High concentration formulation developability approaches and considerations.高浓度制剂开发的方法和考虑因素。
MAbs. 2023 Jan-Dec;15(1):2211185. doi: 10.1080/19420862.2023.2211185.
4
Site Identification by Ligand Competitive Saturation-Biologics Approach for Structure-Based Protein Charge Prediction.基于配体竞争饱和的生物大分子方法进行基于结构的蛋白电荷预测的位点鉴定。
Mol Pharm. 2023 May 1;20(5):2600-2611. doi: 10.1021/acs.molpharmaceut.3c00064. Epub 2023 Apr 5.
5
US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives.美国食品药品监督管理局批准的高浓度制剂治疗性抗体:概述与展望。
Antib Ther. 2021 Nov 18;4(4):262-272. doi: 10.1093/abt/tbab027. eCollection 2021 Oct.
6
Development challenges of high concentration monoclonal antibody formulations.高浓度单克隆抗体制剂的开发挑战。
Drug Discov Today Technol. 2020 Dec;37:31-40. doi: 10.1016/j.ddtec.2020.08.005. Epub 2020 Nov 24.
7
Ongoing Challenges to Develop High Concentration Monoclonal Antibody-based Formulations for Subcutaneous Administration: Quo Vadis?开发用于皮下给药的高浓度单克隆抗体制剂面临的持续挑战:何去何从?
J Pharm Sci. 2022 Apr;111(4):861-867. doi: 10.1016/j.xphs.2021.11.008. Epub 2021 Nov 20.
8
Spray layering of human immunoglobulin G: Optimization of formulation and process parameters.喷雾层层包裹人免疫球蛋白 G:配方和工艺参数的优化。
Int J Pharm. 2021 Dec 15;610:121238. doi: 10.1016/j.ijpharm.2021.121238. Epub 2021 Nov 5.
9
Rapid and accurate estimation of protein-ligand relative binding affinities using site-identification by ligand competitive saturation.利用配体竞争饱和法进行位点鉴定,快速准确地估计蛋白质-配体相对结合亲和力。
Chem Sci. 2021 May 25;12(25):8844-8858. doi: 10.1039/d1sc01781k. eCollection 2021 Jul 1.
10
Understanding the Impact of Protein-Excipient Interactions on Physical Stability of Spray-Dried Protein Solids.了解蛋白质-赋形剂相互作用对喷雾干燥蛋白质固体物理稳定性的影响。
Mol Pharm. 2021 Jul 5;18(7):2657-2668. doi: 10.1021/acs.molpharmaceut.1c00189. Epub 2021 Jun 7.

辅料与单克隆抗体PGT121和N49P9.6-FR-LS之间的相互作用研究:全面分析

Investigating the Interaction between Excipients and Monoclonal Antibodies PGT121 and N49P9.6-FR-LS: A Comprehensive Analysis.

作者信息

Li Xun, Orr Asuka A, Sajadi Mohammad M, DeVico Anthony L, Deredge Daniel J, MacKerell Alexander D, Hoag Stephen W

机构信息

School of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland 21201, United States.

Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.

出版信息

Mol Pharm. 2025 Apr 7;22(4):1831-1846. doi: 10.1021/acs.molpharmaceut.4c00973. Epub 2025 Mar 3.

DOI:10.1021/acs.molpharmaceut.4c00973
PMID:40029670
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11975482/
Abstract

N49P9.6-FR-LS and PGT121 are promising antibodies with significant therapeutic potential against HIV infection, but they are prone to precipitation at concentrations greater than 12 to 13 mg/mL. This study evaluates the influence of six excipients─arginine, alanine, sucrose, trehalose, methionine, and glutamate─on the biophysical stability of antibodies. We employed a comprehensive approach, combining computational mAb-excipient interaction analysis via the site-identification by ligand competitive saturation (SILCS) method with extensive experimental characterization. Our experimental matrix included viscosity measurements across temperature gradients, particle size distribution, zeta potential, pH value, and solution appearance, alongside a short-term stability product study at 30 °C and 65% relative humidity, with assessments at t (initial), t (14 days), and t (28 days). Results indicated that sucrose, arginine, alanine, and trehalose provided varying degrees of stabilization for both antibodies. Conversely, glutamate destabilized PGT121 but stabilized N49P9.6-FR-LS, while methionine had a negative effect on N49P9.6-FR-LS but a positive one on PGT121. SILCS-Biologics analysis suggested that stabilization by these excipients is linked to their ability to occupy regions involved in self-protein interactions. Debye-Hückel-Henry charge calculations further indicated that neutral excipients like sucrose and trehalose could alter mAb charges by affecting buffer binding, influencing aggregation propensity. These findings offer valuable insights for optimizing antibody formulations, ensuring enhanced product stability and therapeutic efficacy for HIV treatment.

摘要

N49P9.6-FR-LS和PGT121是有前景的抗体,具有抗HIV感染的显著治疗潜力,但它们在浓度大于12至13 mg/mL时容易沉淀。本研究评估了六种辅料(精氨酸、丙氨酸、蔗糖、海藻糖、蛋氨酸和谷氨酸)对抗体生物物理稳定性的影响。我们采用了一种综合方法,将通过配体竞争饱和位点识别(SILCS)方法进行的计算单克隆抗体-辅料相互作用分析与广泛的实验表征相结合。我们的实验矩阵包括跨温度梯度的粘度测量、粒度分布、zeta电位、pH值和溶液外观,以及在30°C和65%相对湿度下的短期稳定性产品研究,并在t(初始)、t(14天)和t(28天)进行评估。结果表明,蔗糖、精氨酸、丙氨酸和海藻糖对两种抗体都提供了不同程度的稳定性。相反,谷氨酸使PGT121不稳定,但使N49P9.6-FR-LS稳定,而蛋氨酸对N49P9.6-FR-LS有负面影响,但对PGT121有正面影响。SILCS-生物制剂分析表明,这些辅料的稳定作用与其占据参与自身蛋白质相互作用区域的能力有关。德拜-休克尔-亨利电荷计算进一步表明,蔗糖和海藻糖等中性辅料可通过影响缓冲液结合来改变单克隆抗体的电荷,从而影响聚集倾向。这些发现为优化抗体制剂提供了有价值的见解,确保提高HIV治疗产品的稳定性和治疗效果。